vs
CIVISTA BANCSHARES, INC.（CIVB）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
CIVISTA BANCSHARES, INC.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.3倍（$47.3M vs $35.5M），CIVISTA BANCSHARES, INC.净利率更高（31.7% vs -304.2%，领先336.0%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 11.3%）
Civista Bancshares Inc.是一家总部位于美国的银行控股公司，主要在中西部地区运营，面向零售客户、本地中小企业及社区群体提供个人与商业银行服务，包括存款账户、各类贷款产品及财富管理解决方案。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CIVB vs RXRX — 直观对比
营收规模更大
CIVB
是对方的1.3倍
$35.5M
净利率更高
CIVB
高出336.0%
-304.2%
两年增速更快
RXRX
近两年复合增速
11.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $47.3M | $35.5M |
| 净利润 | $15.0M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 31.7% | -304.2% |
| 营收同比 | — | 681.7% |
| 净利润同比 | 47.4% | 39.6% |
| 每股收益（稀释后） | $0.72 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CIVBRXRX
| Q1 26 | $47.3M | — | ||
| Q4 25 | $46.3M | $35.5M | ||
| Q3 25 | $44.2M | $5.2M | ||
| Q2 25 | $41.4M | $19.2M | ||
| Q1 25 | $40.6M | $14.7M | ||
| Q4 24 | $40.4M | $4.5M | ||
| Q3 24 | $39.3M | $26.1M | ||
| Q2 24 | $38.1M | $14.4M |
净利润CIVBRXRX
| Q1 26 | $15.0M | — | ||
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $12.8M | $-162.3M | ||
| Q2 25 | $11.0M | $-171.9M | ||
| Q1 25 | $10.2M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $8.4M | $-95.8M | ||
| Q2 24 | $7.1M | $-97.5M |
毛利率CIVBRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% |
营业利润率CIVBRXRX
| Q1 26 | — | — | ||
| Q4 25 | 31.8% | -304.8% | ||
| Q3 25 | 35.4% | -3327.6% | ||
| Q2 25 | 31.1% | -916.8% | ||
| Q1 25 | 29.4% | -1297.9% | ||
| Q4 24 | 28.2% | -4042.4% | ||
| Q3 24 | 25.2% | -377.1% | ||
| Q2 24 | 21.2% | -697.4% |
净利率CIVBRXRX
| Q1 26 | 31.7% | — | ||
| Q4 25 | — | -304.2% | ||
| Q3 25 | 28.9% | -3135.3% | ||
| Q2 25 | 26.6% | -894.2% | ||
| Q1 25 | 25.0% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | 21.3% | -367.5% | ||
| Q2 24 | 18.5% | -676.6% |
每股收益（稀释后）CIVBRXRX
| Q1 26 | $0.72 | — | ||
| Q4 25 | $0.59 | $-0.17 | ||
| Q3 25 | $0.68 | $-0.36 | ||
| Q2 25 | $0.71 | $-0.41 | ||
| Q1 25 | $0.66 | $-0.50 | ||
| Q4 24 | $0.62 | $-0.56 | ||
| Q3 24 | $0.53 | $-0.34 | ||
| Q2 24 | $0.45 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $553.9M | $1.1B |
| 总资产 | $4.3B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CIVBRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M |
总债务CIVBRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M |
股东权益CIVBRXRX
| Q1 26 | $553.9M | — | ||
| Q4 25 | $543.5M | $1.1B | ||
| Q3 25 | $499.0M | $1.0B | ||
| Q2 25 | $404.1M | $919.1M | ||
| Q1 25 | $397.4M | $933.9M | ||
| Q4 24 | $388.5M | $1.0B | ||
| Q3 24 | $394.4M | $524.6M | ||
| Q2 24 | $373.8M | $584.4M |
总资产CIVBRXRX
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $1.5B | ||
| Q3 25 | $4.1B | $1.4B | ||
| Q2 25 | $4.2B | $1.3B | ||
| Q1 25 | $4.1B | $1.3B | ||
| Q4 24 | $4.1B | $1.4B | ||
| Q3 24 | $4.1B | $726.5M | ||
| Q2 24 | $4.0B | $775.9M |
负债/权益比CIVBRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CIVBRXRX
| Q1 26 | — | — | ||
| Q4 25 | $43.3M | $-46.1M | ||
| Q3 25 | $19.0M | $-117.4M | ||
| Q2 25 | $11.1M | $-76.4M | ||
| Q1 25 | $3.6M | $-132.0M | ||
| Q4 24 | $48.2M | $-115.4M | ||
| Q3 24 | $12.9M | $-59.2M | ||
| Q2 24 | $12.2M | $-82.2M |
自由现金流CIVBRXRX
| Q1 26 | — | — | ||
| Q4 25 | $42.1M | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | $3.5M | $-133.8M | ||
| Q4 24 | $44.1M | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M |
自由现金流率CIVBRXRX
| Q1 26 | — | — | ||
| Q4 25 | 90.9% | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | 8.5% | -907.4% | ||
| Q4 24 | 109.1% | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% |
资本支出强度CIVBRXRX
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | 0.4% | 12.4% | ||
| Q4 24 | 10.4% | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% |
现金转化率CIVBRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.49× | — | ||
| Q2 25 | 1.01× | — | ||
| Q1 25 | 0.36× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 1.73× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CIVB
| Net Interest Income | $37.8M | 80% |
| Noninterest Income | $9.4M | 20% |
RXRX
暂无分部数据
